Sotatercept (Winrevair)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses Winrevair (sotatercept), 45 mg or 60 mg, powder and solvent for injectable solution. Indication: In combination with standard pulmonary arterial hypertension (PAH) therapy, for the treatment of adults with WHO Group 1 PAH and Functional Class II or III.